Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
4basebio PLC (88Q.DE)
EUR5.90
+0.00 (+0.00%)
GB XETRA Healthcare Biotechnology
Address
25 Norman Way
Cambridge, GB
Cambridge, GB
CEO
Amy Jo Walker
Website
4basebio.com
IPO
2021-11-23
ISIN GB00BMCLYF79
Also trades on
Deutsche Börse · 88Q.DE (EUR)
Frankfurt Stock Exchange · 88Q.F (EUR)
London Stock Exchange · 4BB.L (GBp)
Description
4basebio Plc operates as a biotechnology firm dedicated to the creation of advanced therapeutic medicinal products. Its strategy involves utilizing synthetic DNA and non-viral platforms specifically engineered for targeted nucleic acid delivery to cells. The company actively produces and supplies premium synthetic DNA suitable for diverse applications, including research, therapeutic interventions, and pharmacological uses. Moreover, 4basebio develops specialized non-viral vectors, designed to ensure the effective transportation of various therapeutic payloads within patients. This enterprise was established on December 22, 2020, and maintains its principal office in Cambridge, United Kingdom.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR5.90
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
312
Beta
0.87
Float Shares
5.70M
Free Float %
36.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.78% | -0.94% | -7.89% | -16.00% | -34.78% | -21.64% | -60.23% | -20.45% | -38.24% | -38.24% | -38.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
5.90
Quality scores
Altman Z-Score
-2.83
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+81.6% ★ Q4'25: +93.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-16.0% Q4'25: -70.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-931.5% Q4'25: -1,786.9% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-988.0% Q4'25: -1,637.0% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: -397.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+18.2% Q4'25: +26.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×— Q4'25: -0.49× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
462.0K
est: 446.9K (+3.4%)
|
338.0K
est: 356.8K (-5.3%)
|
268.0K
est: 339.0K (-20.9%)
|
506.0K
est: 576.7K (-12.3%)
|
933.0K
est: 1.10M (-15.2%)
|
1.69M
est: 1.70M (-0.4%)
|
2.63M
2.63M – 2.63M
+54.3% YoY
|
15.15M
15.15M – 15.15M
+476.9% YoY
|
25.24M
25.24M – 25.24M
+66.7% YoY
|
35.34M
35.34M – 35.34M
+40.0% YoY
|
| EBITDA |
-346.0K
est: -409.6K (+15.5%)
|
-3.21M
est: -327.1K (-880.6%)
|
-5.41M
est: -299.8K (-1,704.0%)
|
-7.34M
est: -547.7K (-1,240.7%)
|
-10.97M
est: -1.10M (-897.0%)
|
-15.59M
est: -1.70M (-816.6%)
|
-2.63M
-2.63M – -2.63M
-54.3% YoY
|
-15.15M
-15.15M – -15.15M
-476.9% YoY
|
-25.24M
-25.24M – -25.24M
-66.7% YoY
|
-35.34M
-35.34M – -35.34M
-40.0% YoY
|
| EBIT |
-622.0K
est: -446.9K (-39.2%)
|
-3.53M
est: -356.8K (-888.5%)
|
-5.84M
est: -339.0K (-1,622.7%)
|
-8.05M
est: -576.7K (-1,296.3%)
|
-11.90M
est: -1.10M (-981.7%)
|
-16.74M
est: -1.70M (-883.9%)
|
-2.63M
-2.63M – -2.63M
-54.3% YoY
|
-15.15M
-15.15M – -15.15M
-476.9% YoY
|
-25.24M
-25.24M – -25.24M
-66.7% YoY
|
-35.34M
-35.34M – -35.34M
-40.0% YoY
|
| Net Income |
-719.0K
est: -1.46M (+50.9%)
|
-3.24M
est: -3.31M (+2.3%)
|
-5.15M
est: -5.02M (-2.6%)
|
-7.67M
est: -7.88M (+2.8%)
|
-12.33M
est: -13.50M (+8.7%)
|
-16.92M
est: -17.07M (+0.9%)
|
-15.66M
-15.66M – -15.66M
+8.3% YoY
|
-12.21M
-12.21M – -12.21M
+22.0% YoY
|
-7.83M
-7.83M – -7.83M
+35.9% YoY
|
-4.70M
-4.70M – -4.70M
+40.0% YoY
|
| SGA |
657.0K
est: 1.93M (-65.9%)
|
1.86M
est: 1.54M (+20.7%)
|
2.96M
est: 1.46M (+102.3%)
|
1.54M
est: 2.64M (-41.6%)
|
1.77M
est: 6.97M (-74.7%)
|
17.29M
est: 10.77M (+60.4%)
|
16.63M
16.63M – 16.63M
+54.3% YoY
|
95.93M
95.93M – 95.93M
+476.9% YoY
|
159.88M
159.88M – 159.88M
+66.7% YoY
|
223.83M
223.83M – 223.83M
+40.0% YoY
|
| EPS |
-0.06
est: -0.12 (+50.9%)
|
-0.26
est: -0.27 (+3.3%)
|
-0.42
est: -0.41 (-3.1%)
|
-0.62
est: -0.60 (-3.1%)
|
-0.94
est: -0.87 (-8.0%)
|
-1.09
est: -1.10 (+1.0%)
|
-1.01
-1.01 – -1.01
+8.3% YoY
|
-0.79
-0.79 – -0.79
+22.0% YoY
|
-0.50
-0.50 – -0.50
+35.9% YoY
|
-0.30
-0.30 – -0.30
+40.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-18.72M
OE per share TTM
-1.31
Owner's Yield
-22.94%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
466.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-1.7K
Shares Outstanding
15.48M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Amy Walker | CEO & Director | 356.9K | female |
| Christine Wolosin | Chief Commercial Officer | — | female |
| Jennifer Gelman | Vice President of Marketing | — | female |
| Manja Hermina Elisabeth Maria Boerman | Executive Chair of the Board | — | — |
| Scott Lorimer | Chief Operating Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 88Q.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
